INSYS Therapeutics Receives FDA Fast Track Designation for Epinephrine Nasal Spray

INSYS Therapeutics, Inc. (INSY) announced on August 30 that the company received a Fast Track from the FDA for the company’s epinephrine nasal spray. The spray is an investigational drug for the treatment of anaphylaxis, a life-threatening allergic reaction requiring urgent treatment. INSYS is a leader in the development, manufacture, and commercialization of pharmaceutical cannabinoids […]

Read more...

Analog Devices Share Repurchase Program Increases by $2 Billion

On August 21, Analog Devices, Inc. (ADI) announced that the company’s Board of Directors voted to reinstate their share repurchase program. The company’s existing share repurchase program started in 2004, and Analog Devices has repurchased $5.4 billion in stock since that time. This reinstatement increases the total authorization by an additional $2 billion.   At […]

Read more...

July 2018 Scorecard

The July 2018 scorecard for the signals generated from Sonal can be downloaded here. For more information regarding how you can trade these signals, see the article The Three Moves for Event Based Trading Try Sonal 30 days for free and cancel anytime! Subscribe here and check out the Quickstart Guide FacebookGoogle+Twitter

Read more...

Regeneron Pharmacueticals and Teva Pharmaceutical Report Positive Topline Phase 3 Clinical Trial Results of Fasinumab

On August 16, Regeneron Pharmaceuticals, Inc. (REGN) and Teva Pharmaceutical Industries Ltd. (TEVA) announced positive topline results from a Phase 3 clinical trial of Fasinumbab in patients with chronic pain from osteoarthritis of the knee or hip. After 16 weeks, the study met both co-primary endpoints as well as all key secondary endpoints. Patients treated […]

Read more...

Strongbridge Biopharma Reports Positive Results in Phase 3 SONICS Study of RECORLEV

On August 8, Strongbridge Biopharma plc (SBBP) announced top-line results from its Phase 3 SONICS study evaluating RECORLEVTM(levoketoconazole) for the treatment of endogenous Cushing’s syndrome. The open-label, single-arm SONICS study produced statistically significant results of its pre-specified primary endpoint. At six months, 30% of patients demonstrated a normalization rate of Urinary Free Cortisol. Sonal alerted […]

Read more...

Horizon Pharma Reports Second Quarter Earnings and Increases Annual Guidance

Horizon Pharma plc (HZNP) reported its second-quarter 2018 earnings on August 8. Net sales increased by 4.6% due to strong growth for its orphan and rheumatology medicines. The company increased its annual adjusted EBITDA guidance to between $400 million and $420 million. Horizon Pharma has realigned its operating structure into two segments so that it […]

Read more...

Fortune Brands Home & Security Increases Annual Earnings Outlook on Strong Second-Quarter Sales Results

Fortune Brands Home & Security, Inc. (FBHS) announced its second-quarter 2018 earnings on July 26. Sales increased 5% year-over-year to $1.4 billion. The company increased its guidance for annual EPS before charges/gains to between $3.62 and $3.72.   Sonal issued an alert to subscribers at 4:05 pm. The next trade was for $53.97 at 4:06 […]

Read more...